Human DR3 (TL1A receptor) (Luc) Jurkat Reporter Cell Development Service
描述（Description）
The Human DR3 (TL1A receptor) (Luc) Jurkat Reporter Cell was engineered to not only express the NF-κB signaling response element, but also express the receptor human DR3 (TL1A receptor) (Gene ID: 8718). When stimulated with human TL1A protein, the TL1A/DR3 interaction drives NF-κB-mediated luminescence. Inhibition of TL1A binding to DR3 by either anti-TL1A or anti-DR3 antibodies results in a decrease in luminescence.
应用说明（Application）
Screen for neutralizing antibodies blocking the stimulation of human TL1A protein.
生长特性（Growth Properties）
Suspension
筛选标记（Selection Marker）
Hygromycin (20 μg/mL)
培养基（Culture Medium）
RPMI-1640 + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) is also known as Apo-3, Death receptor 3 (DDR3 or DR3), Apoptosis-inducing receptor AIR, Apoptosis-mediating receptor TRAMP, Lymphocyte-associated receptor of death, Apo-3, which is a member of the TNF-receptor superfamily. TNFRSF25 is a homodimer protein, which can Interact strongly via the death domains with TNFRSF1 and TRADD to activate at least two distinct signaling cascades, apoptosis and NF-kappa-B signaling. TNFRSF25 is receptor for TNFSF12 / APO3L / TWEAK.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
关键字： DR3报告细胞系;DR3报告细胞株;DR3细胞系;DR3细胞株;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。